{"id":"doi:10.1007/s00262-023-03386-7","kind":"article","title":"Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer","authors":["Yu YJ","Shan N","Li LY","Zhu YS","Lin LM","Mao CC","Hu TT","Xue XY","Su XP","Shen X","Cai ZZ"],"author_count":11,"year":2023,"published":"2023-02-16","venue":"Cancer immunology, immunotherapy : CII","cited_by":25,"doi":"10.1007/s00262-023-03386-7","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1007/s00262-023-03386-7","archive_url":"https://space-kitty.com/papers/doi:10.1007/s00262-023-03386-7","updated":null,"pmid":"36795124","pmcid":"PMC10264512","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC10264512/pdf","abstract":"Immunotherapy based on immune checkpoint inhibitors (ICIs) has provided revolutionary results in treating various cancers. However, its efficacy in colorectal cancer (CRC), especially in microsatellite stability-CRC, is limited. This study aimed to observe the efficacy of personalized neoantigen vaccine in treating MSS-CRC patients with recurrence or metastasis after surgery and chemotherapy. Candidate neoantigens were analyzed from whole-exome and RNA sequencing of tumor tissues. The safety and immune response were assessed through adverse events and ELISpot. The clinical response was evaluated by progression-free survival (PFS), imaging examination, clinical tumor marker detection, circulating tumor DNA (ctDNA) sequencing. Changes in health-related quality of life were measured by the FACT-C scale. A total of six MSS-CRC patients with recurrence or metastasis after surgery and chemotherapy were administered with personalized neoantigen vaccines. Neoantigen-specific immune response was observed in 66.67% of the vaccinated patients. Four patients remained progression-free up to the completion of clinical trial. They also had a significantly longer progression-free survival time than the other two patients without neoantigen-specific immune response (19 vs. 11 months). Changes in health-related quality of life improved for almost all patients after the vaccine treatment. Our results shown that personalized neoantigen vaccine therapy is likely to be a safe, feasible and effective strategy for MSS-CRC patients with postoperative recurrence or metastasis.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer\" by Yu YJ, Shan N, Li LY et al., https://doi.org/10.1007/s00262-023-03386-7, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","domain_slug":"medicine"}],"cited_in_dossiers":[]}